Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)
Non-Small-Cell Lung Cancer
DRUG: Golidocitinib|DRUG: Sintilimab|DRUG: platinum doublet chemotherapy
Overall response rate (ORR) (cohort1), Complete response (CR) or partial response (PR) per investigator assessment according to RECIST 1.1, through study completion, an average of 1 year|Progression-free survival (PFS) (cohort2), Time from first administration of study drug to first documented disease progression or death per investigator assessment according to RECIST 1.1, through study completion, an average of 1 year
Overall survival (OS), time from first administration of study drug to death, through study completion, up to 36 months|Incidence of Adverse Events, Frequency an severity of AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0., through study completion, up to 36 months
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC)